GlobeNewswire: Assembly Biosciences, Inc. Contains the last 10 of 223 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:04:47ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/08/2825969/0/en/Assembly-Biosciences-Announces-Effective-Date-of-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Announces Effective Date of Reverse Stock Split2024-02-08T13:00:00Z<![CDATA[– Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 –]]>https://www.globenewswire.com/news-release/2024/01/04/2803936/0/en/Assembly-Biosciences-Provides-Anticipated-Development-Milestones-for-2024.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Provides Anticipated Development Milestones for 20242024-01-04T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.]]>https://www.globenewswire.com/news-release/2023/11/10/2778507/0/en/Assembly-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2023-11-10T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.]]>https://www.globenewswire.com/news-release/2023/11/10/2778276/0/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Viral-Hepatitis-Portfolio-at-AASLD-The-Liver-Meeting.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®2023-11-10T13:00:00Z<![CDATA[--Poster highlights potential of oral small molecule IFNAR agonist program to engage the IFNα pathway through a liver-focused approach to improve tolerability--SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.]]>https://www.globenewswire.com/news-release/2023/11/08/2776699/0/en/Assembly-Biosciences-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Updates.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates2023-11-08T21:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.]]>https://www.globenewswire.com/news-release/2023/11/08/2776175/0/en/Assembly-Biosciences-Names-Anuj-Gaggar-MD-PhD-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer2023-11-08T13:00:00Z<![CDATA[-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs --SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infections.]]>https://www.globenewswire.com/news-release/2023/10/11/2758302/0/en/Assembly-Biosciences-to-Present-New-Data-at-AASLD-The-Liver-Meeting.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences to Present New Data at AASLD The Liver Meeting®2023-10-11T12:00:00Z<![CDATA[-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program --SOUTH SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that preclinical and clinical data from its virology portfolio will be featured in two presentations at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.]]>https://www.globenewswire.com/news-release/2023/10/02/2752700/0/en/Assembly-Biosciences-Nominates-Development-Candidate-ABI-6250-an-Orally-Bioavailable-HDV-Entry-Inhibitor.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor2023-10-02T12:00:00Z<![CDATA[− ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected –]]>https://www.globenewswire.com/news-release/2023/09/19/2746015/0/en/Assembly-Biosciences-to-Highlight-Pipeline-Progress-in-HBV-and-HDV-at-the-2023-International-HBV-Meeting.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting2023-09-19T20:05:00Z<![CDATA[-- Two oral presentations and one poster will feature new data from the Company’s hepatitis B/hepatitis D entry inhibitor, capsid assembly modulator ABI-4334, and interferon-alpha receptor agonist programs --SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the company will present new preclinical data from multiple hepatitis B virus (HBV) and hepatitis D virus (HDV) pipeline programs at the 2023 International HBV Meeting taking place in Kobe, Japan, September 19-23, 2023.]]>https://www.globenewswire.com/news-release/2023/08/09/2722123/0/en/Assembly-Biosciences-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Updates.html?f=22&fvtc=4&fvtv=13058Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates2023-08-09T20:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent updates for the second quarter ended June 30, 2023.]]>